AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Frederik Marmé'
:
Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-gs1-02
Abstract:
Add to Library
Authors:
Sibylle Loibl
Frederik Marmé
Miguel Martín
Michael Untch
Hervé Bonnefoi
Sung‐Bae Kim
Harry D. Bear
Nicole Mc Carthy
Mireia Melé
Karen A. Gelmon
J. García Saenz
Catherine M. Kelly
Toralf Reimer
Masakazu Toi
Hope S. Rugo
Sabine Seiler
Valentina Nekljudova
Carsten Denkert
Michael Gnant
Andreas Makris
Nicole Burchardi
Gϋnter von Minckwitz
Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-gs1-11
Abstract:
Add to Library
Authors:
Hope Rugo
Aditya Bardia
Frederik Marmé
Javier Cortés
Peter Schmid
Delphine Loirat
Olivier Trédan
Eva Ciruelos
Florence Dalenc
P. Gómez Pardo
Komal Jhaveri
Monica Motwani
Oh Kyu Yoon
Hao Wang
Wendy Verret
Sara M. Tolaney
Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-ct158
Abstract:
Add to Library
Authors:
Shannon N. Westin
Rebecca Kristeleit
Robert L. Coleman
Keiichi Fujiwara
Amit M. Oza
David M. O’Malley
Thomas J. Herzog
Frederik Marmé
Ana Oaknin
Ramez N. Eskander
Domenica Lorusso
Tamar Safra
Jacob Korach
Kevin Lin
Danny Shih
Lisa Caunt
Sandra Goble
Stephanie Hume
Lara Maloney
Iain A. McNeish
Bradley J. Monk
Cre recombinase‐mediated gene targeting of mesenchymal cells
Publication Year: 2004
DOI: https://doi.org/10.1002/gene.20004
Abstract:
Add to Library
Authors:
Lore Florin
Heike Alter
Hermann‐Josef Gröne
Axel Szabowski
Günther Schütz
Peter Angel
Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd9-04
Abstract:
Add to Library
Authors:
Chiara Massa
Thomas Karn
Karsten E. Weber
Andreas Schneeweiß
Claus Hanusch
Jens‐Uwe Blohmer
Dirk-Michael Zahm
Christian Jackisch
Marion van Mackelenbergh
Jörg Thomalla
Frederik Marmé
Jens Huober
Volkmar Müller
Christian Schem
Anja Müller
Elmar Stickeler
Katharina Biehl
Peter A. Fasching
Michael Untch
Sibylle Loibl
Carsten Denkert
Barbara Seliger
Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-her2-06
Abstract:
Add to Library
Authors:
Carsten Denkert
M Navarro
Michael Untch
Hervé Bonnefoi
Erik S. Knudsen
Seock‐Ah Im
Angela DeMichele
Agnieszka K. Witkiewicz
Laura van ‘t Veer
Sung‐Bae Kim
Harry D. Bear
Nicole McCarthy
Karen Gelmon
Frederik Marmé
José Á. García-Sáenz
Nicholas Turner
Federico Rojo
Martin Filipits
Lesley‐Ann Martin
Peter A. Fasching
Christian Schem
Catherine M. Kelly
Toralf Reimer
Masakazu Toi
Hope Rugo
Michael Gnant
Andreas Makris
Yuan Liu
Karsten E. Weber
Sivaramakrishna Rachakonda
Sibylle Loibl
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1016/j.annonc.2022.03.008
Abstract:
Add to Library
Authors:
Andrew Tutt
John J. Garber
R.D. Gelber
Kelly‐Anne Phillips
Andrea Eisen
Oskar T. Johannsson
Priya Rastogi
Karen Cui
S-A. Im
R. Yerushalmi
Adam Brufsky
Maria Taboada
Giovanna Rossi
Greg Yothers
C Singer
Luis Fein
Niklas Loman
David Cameron
Christine Campbell
CE Geyer
Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)
Publication Year: 2015
DOI: https://doi.org/10.1158/1538-7445.sabcs14-p5-19-06
Abstract:
Add to Library
Authors:
Hans Tesch
Oliver J. Stoetzer
Thomas Decker
Christian M. Kurbacher
Romy Neumeister
Frederik Marmé
A Schneeweis
Christoph Mundhenke
Andrea Distelrath
Peter A. Fasching
Michael P. Lux
Diana Lueftner
Peyman Hadji
Wolfgang Janni
Mathias Muth
Julia Kreuzeder
Claudia Weiß
D. Wallwiener
Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-05
Abstract:
Add to Library
Authors:
Luc Dirix
Hans Wildiers
Manon Huizing
Eveline Cuypere
Carolina P. Schröder
Anne Armstrong
J. Huober
Frederik Marmé
Andreas Schneeweiß
Sarah Khan
Frédéric Triebel
Abstract P4-01-01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-p4-01-01
Abstract:
Add to Library
Authors:
Christian Jackisch
Cosima Brucker
Thomas Decker
Anne Engel
Peter A. Fasching
Thomas Göhler
Jan Janssen
Andreas Köhler
Kerstin Lüdtke-Heckenkamp
Diana Lüftner
Marion van Mackelenbergh
Frederik Marmé
Arnd Nusch
Beate Rautenberg
Toralf Reimer
Marcus Schmidt
Rudolf Weide
Pauline Wimberger
Christian Roos
Achim Wöckel
Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-p4-07-65
Abstract:
Add to Library
Authors:
Frederik Marmé
Aditya Bardia
Hope Rugo
Peter Schmid
Sara M. Tolaney
Mafalda Oliveira
Andreas Schneeweiß
Ling Shi
Wendy Verret
Mahdi Gharaibeh
Anju Shah
Javier Cortés
COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer
Publication Year: 2018
DOI: https://doi.org/10.1007/s10549-018-4983-8
Abstract:
Add to Library
Authors:
Katharina Smetanay
P. R. M. Nogueira Junio
Manuel Feißt
Julia Seitz
Jessica C. Hassel
Luisa Mayer
Lina Maria Matthies
A. Schumann
André Hennigs
Jörg Heil
Christof Sohn
Dirk Jaeger
Andreas Schneeweiß
Frederik Marmé
Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC)
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-p3-07-08
Abstract:
Add to Library
Authors:
Sara M. Tolaney
Peter Schmid
Aditya Bardia
Frederik Marmé
Delphine Loirat
Priyanka Sharma
Hao Wang
Olivia Fu
Wendy Verret
Hope Rugo
Abstract P1-19-33: Real-world efficacy of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Second interim analysis from the RIBANNA study
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-p1-19-33
Abstract:
Add to Library
Authors:
Achim Wöckel
Pawel Basiora
Michael K. Bohlmann
Thomas Decker
Jörg Falbrede
Peter A. Fasching
Helmut Forstbauer
Tobias Hesse
Oliver Hoffmann
Christian Jackisch
Anna Kaczerowsky
Ralf Lorenz
Kerstin Lüdtke-Heckenkamp
Diana Lüftner
Frederik Marmé
Thomas E. Mueller
Christoph Mundhenke
Arnd Nusch
Volker Petersen
Gabriele Prange‐Krex
Toralf Reimer
Thomas Resch
Christian Roos
Oliver Tomé
Anja Weishap
Abstract PD13-10: PD13-10 Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2- ABC): Exploratory Analysis of the PARSIFAL Trial
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd13-10
Abstract:
Add to Library
Authors:
Serena Di Cosimo
José Manuel Pérez-García
Meritxell Bellet Ezquerra
Florence Dalenc
Miguel Gil Gil
Manuel Ruíz Borrego
Joaquín Gavilá
Miguel Sampayo-Cordero
Elena Aguirre
Peter Schmid
Frederik Marmé
Joseph Gligorov
Andreas Schneeweiß
Joan Albanell
Pilar Zamora
Duncan Wheatley
Eduardo Martínez de Dueñas
Vicente Carañana
Kepa Amillano
Andrea Malfettone
Javier Cortés
Antonio Llombart–Cussac
Found 56 results in 0.071 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"